RxDoctor Payments Data

Anita Krishnarao, MD

Gastroenterology · Worcester, MANPI 1114365921

Payments from drug & device makers

$91,110in general payments, 2019–2025

Across 80 payments — averaging $1138.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$83K
  • Daiichi Sankyo Inc.$8K
  • Boston Scientific$177
  • Veloxis Pharmaceuticals, Inc.$168
  • Fujifilm Healthcare Americas Corporation$113
  • Regeneron Healthcare Solutions, Inc.$71
  • plus $71 from 2 others

What the payments were for

  • Consulting fees$6,23015%
  • Speaking & faculty fees$27,41568%
  • Travel & lodging$4,43811%
  • Food & beverage$2,2506%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,110 in reported general payments places this provider in the 85th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$45,095
Medicare patients
197
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin40$136,791
CreonLipase/Protease/Amylase13$31,807
Ursodiol122$19,049
Tacrolimus151$12,958
Cyclosporine17$11,052
Envarsus XrTacrolimus23$9,049
SpsSodium Polystyrene Sulfon/Sorb12$6,885
Sirolimus15$4,830
Midodrine Hcl13$3,090
Lactulose32$2,008
Cyclosporine ModifiedCyclosporine, Modified18$1,960
Mycophenolate Mofetil32$1,177
Entecavir31$904
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$843
Spironolactone43$842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$27$31,80713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →